The European Commission has approved  Abbott’s HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn’s disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. 

read more

via Science 2.0 Read More…

Advertisements